Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
GlaxoSmithKline (United States) · Research Triangle Park Foundation
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
668
total citations
- FWCI
- 9.30
- Percentile
- 100%
- References
- 37
Citations per year
Authors
9- WXWenle XiaCorresponding
- RJRobert J. Mullin
GlaxoSmithKline (United States), Research Triangle Park Foundation
- BRBarry R. Keith
GlaxoSmithKline (United States), Research Triangle Park Foundation
- LLLei-Hua Liu
GlaxoSmithKline (United States), Research Triangle Park Foundation
- HMHong Ma
GlaxoSmithKline (United States), Research Triangle Park Foundation
Topics & keywords
Topics
Keywords
- Protein kinase B
- Cancer research
- Biology
- Receptor tyrosine kinase
- PI3K/AKT/mTOR pathway
- EGFR inhibitors
- Tyrosine kinase
- Phosphorylation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.